Beta adrenergic blockade and decompensated cirrhosis.

Area of Science:

• Hepatology
• Cardiology
• Nephrology

Background:

• Non-selective betablockers (NSBBs) are standard for portal hypertension.
• Efficacy data primarily from trials excluding advanced cirrhosis patients.

Observation:

• Emerging evidence suggests potential harm from NSBBs in advanced cirrhosis.
• Concerns include hypotension and limited cardiac reserve.
• Portal hypertension affects systemic hemodynamics, cardiac function, and renal perfusion.

Findings:

• NSBBs effectively prevent variceal bleeding and may offer non-hemodynamic benefits.
• However, NSBBs can induce hypotension and compromise cardiac function.
• The use of NSBBs in advanced cirrhosis is controversial.

Implications:

• Individualized NSBB regimens tailored to cirrhosis stage are needed.
• Optimizing NSBB use can improve patient management in decompensated cirrhosis.
• This article provides practical recommendations for NSBB use in this population.